SUPN Supernus Pharmaceuticals, Inc.
$42.83 +0.16%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
+0.16%
YTD
-10.90%
P/E
—
P/B
2.68
ROE
-10.4%
Div yield
—
Beta
0.45
Market cap
$2.5B
RSI (14)
47
Next earnings
Nov 2, 2026
Previous session
close of Oct 6, 2026 · EOD, no live order bookOpen
$42.86
Close
$42.83
VWAP (n/a)
—
Day high
$43.12
Day low
$41.40
Volume
748K
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
3 Reasons SUPN is Risky and 1 Stock to Buy Instead
Yahoo Finance · Sep 21
Why Did Supernus Pharmaceuticals (SUPN) Move Today?
Yahoo Finance · Sep 19
How Supernus’ Q2 Beat and Raised Guidance Could Reshape Supernus Pharmaceuticals (SUPN) Investors’ Outlook
Yahoo Finance · Sep 18
Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
Yahoo Finance · Sep 18
Supernus Pharmaceuticals to Participate in September Investor Conferences
Yahoo Finance · Sep 2
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?
Yahoo Finance · Aug 24
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
8-K Aug 3, 2026 View → 8-K Aug 3, 2026 View → 10-Q Aug 3, 2026 View → 8-K Aug 3, 2026 View → 8-K Aug 3, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell SUPN. Try it in the Lab to size a position and see the risk.